12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device

Phase 3

Completed

Conditions: Nasal Polyps

Interventions: Drug: Fluticasone Propionate

Registration Number: NCT01623310

Lead Sponsor: Optinose US Inc.

Brief Summary: This is an open-label, multicenter study designed to assess the safety of intranasal administration of 400 μg of fluticasone propionate twice a day delivered by the OptiNose device in subjects with chronic sinusitis with or without nasal polyps. The study consists of an up-to-7-day pretreatment phase followed a 12-month open-label treatment phase. The duration of each subject's participation is approximately 53 weeks.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 223

Inclusion Criteria

Men or women aged 18 years and older Women must
- be practicing an effective method of birth control (eg, prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method [eg, condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel], or male partner sterilization) before entry and throughout the study, or
- be surgically sterile (have had a hysterectomy or bilateral oophorectomy, or tubal ligation at least 1 year before screening) or otherwise be incapable of pregnancy, or
- be postmenopausal (spontaneous amenorrhea for at least 1 year).
Women of child-bearing potential must have a negative serum beta-human chorionic gonadotropin (β-hCG) pregnancy test at the screening visit
Have either:

a history of chronic sinusitis with bilateral nasal polyposis determined by nasoendoscopy at screening visit OR a history of chronic sinusitis (without polyps) for equal to or greater than 12 weeks and currently experiencing 2 or more of the following symptoms, one of which MUST be either nasal blockage/congestion or nasal discharge (anterior and/or posterior nasal discharge):

nasal blockage/congestion
nasal discharge (anterior and/or posterior nasal discharge)
facial pain or pressure
reduction or loss of smell
- Subjects with comorbid asthma or COPD must be stable with no exacerbations (eg, no emergency room visits, hospitalizations, or oral or parenteral steroid use)within the 3 months before the screening visit. Inhaled corticosteroid use must be limited to stable doses of no more than 1,000 μg/day of beclomethasone (or equivalent; See Attachment 1) for at least 3 months before screening with plans to continue use throughout the study.
- Must be able to cease treatment with intranasal steroids and inhaled corticosteroids (except permitted doses listed above for asthma and COPD) at the screening visit
- Must be able to use the OptiNose device correctly; all subjects will be required to demonstrate correct use of the placebo device at the screening visit, see Section 12.1, Visit 1, screening procedures.
- Must be capable, in the opinion of the investigator, of providing informed consent to participate in the study. Subjects must sign an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.

Exclusion Criteria

Women who are pregnant or lactating
Inability to have each nasal cavity examined for any reason, including nasal septum deviation
Nasal septum perforation
Has had more than 1 episode of epistaxis with frank bleeding in the month before the screening visit
Have evidence of significant baseline mucosal injury, ulceration or erosion (eg, exposed cartilage, perforation) on baseline nasal examination/nasoendoscopy
History of sinus or nasal surgery within 6 months before the screening visit
Current, ongoing rhinitis medicamentosa (rebound rhinitis)
Have significant oral structural abnormalities, eg, a cleft palate
Diagnosis of cystic fibrosis
History of Churg-Strauss syndrome or dyskinetic ciliary syndromes
Purulent nasal infection, acute sinusitis, or upper respiratory tract infection within 2 weeks before the screening visit. Potential subjects presenting with any of these infections may be rescreened 4 weeks after symptom resolution
Planned sinonasal surgery during the period of the study
Allergy, hypersensitivity, or contraindication to corticosteroids or steroids
Allergy or hypersensitivity to any excipients in study drug
Exposure to any glucocorticoid treatment with potential for systemic effects (eg, oral, parenteral, intra-articular, or epidural steroids, high dose topical steroids) within 1 month before the screening visit; except as noted in inclusion criteria for subjects with comorbid asthma or COPD
Have nasal candidiasis
Have taken a potent CYP3A4 inhibitor within 14 days before the screening visit; examples of these medications can be found in Section 11.6, Concomitant Medication.
History or current diagnosis of any form of glaucoma or ocular hypertension (ie, intraocular pressure >21 mmHg)
History of intraocular pressure elevation on any form of steroid therapy
History or current diagnosis of the presence (in either eye) of a cataract
Any serious or unstable concurrent disease, psychiatric disorder, or any significant condition that, in the opinion of the investigator could confound the results of the study or could interfere with the subject's participation or compliance in the study
A recent (within 1 year of the screening visit) clinically significant history of drug or alcohol use, abuse, or dependence that, in the opinion of the investigator could interfere with the subject's participation or compliance in the study
Positive urine drug screen at screening visit for drugs of abuse (see Section 14.5), with the exception of prescribed medications for legitimate medical conditions
Have participated in a previous clinical trial of OPTINOSE FLUTICASONE
Have participated in an investigational drug clinical trial within 30 days of the screening visit
Employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
OPN-375 400 μg BID	Fluticasone Propionate	OPN-375 400 μg BID for 12 months

Primary Outcome Measures

Name	Time	Method
Adverse Events	12 Months	Patients with at least one Adverse Events

Secondary Outcome Measures

Name	Time	Method
Summed Bilateral Nasal Polyp Grading Scale Score	Baseline, Month 3, Month 12	In subjects with nasal polyps, polyp grading of each nasal cavity was determined by a nasal polyp grading scale score measured by nasoendoscopy. 0: No polyps 1. Mild polyposis: polyps not reaching below the inferior of the middle turbinate 2. Moderate polyposis: polyps reaching below the inferior border of the middle concha, but not the inferior border of the inferior turbinate 3. Severe polyposis: large polyps reaching below the lower inferior border of the inferior turbinate
Nasal Polyp Surgery Eligibility	Baseline, Month 3, Month 12
Sinonasal Outcome Test 22 (SNOT-22) Total Score	Baseline, Month 3, Month 12	Change from baseline to Month 3 \& Month 12 in SNOT-22 Total Score SNOT-22 is validated in large populations with chronic sinusitis with and without nasal polyps. The 22 questions are used to calculate a total score (the sum of all items) and 4 subscale scores. The 22 questions are divided among 4 subscales: Rhinologic, Ear and Facial Symptoms, Sleep Function, and Psychological Issues subscales. The total score can range from 0-110, 0 being the best and 110 being the worst. 0: No problem 1. Very mild problem 2. Mild or slight problem 3. Moderate problem 4. Severe problem 5. Problem as bad as it can be
Lund-Mackay Total Score	Baseline, Month 3, Month 12	Change from baseline to Month 3, Month 12, in Lund-Mackay Total Score Lund-Mackay Assessment of nasal cavity appearance, via nasoendoscopy, used to evaluate signs of edema, discharge, crusting, scarring/adhesions, and nasal polyps, with each sign rated on a 0 to 2 scale 0: None 2: Worse outcome
Patient Global Impression of Change (PGIC)	Baseline, Month 3, Month 12	The PGIC took less than 1 minute to complete. Subjects answered question, "Since starting the study drug, how would you rate the change in your symptoms?" Patients may answer very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse. Data listed below reports the total number of patients who answered very much improved, much improved, or minimally improved at the specified time.

Trial Locations

Locations (16): Exemplar Research
🇺🇸
Fairmont, West Virginia, United States
Achieve Clinical Research
🇺🇸
Birmingham, Alabama, United States
Sneeze Wheeze and Itch Associates
🇺🇸
Normal, Illinois, United States
PAB Clinical Research
🇺🇸
Brandon, Florida, United States
PMG Research of Winston Salem
🇺🇸
Winston-Salem, North Carolina, United States
Best Clinical Trials
🇺🇸
New Orleans, Louisiana, United States
HCCA Clinical Research Solutions
🇺🇸
Middleburg Heights, Ohio, United States
William Blake Partners
🇺🇸
Grapevine, Texas, United States
Allergy and Asthma Research Group
🇺🇸
Eugene, Oregon, United States
Clinical Research Solutions
🇺🇸
Franklin, Tennessee, United States
Advanced Clinical Research
🇺🇸
West Jordan, Utah, United States
InterMountain Ear Nose and Throat
🇺🇸
Salt Lake City, Utah, United States
Premier Clinical Research
🇺🇸
Spokane, Washington, United States
Allergy Asthma and Sinus Center
🇺🇸
Greenfield, Wisconsin, United States
Professional Research Network of Kansas
🇺🇸
Wichita, Kansas, United States
Focus Clinical Research
🇺🇸
Draper, Utah, United States